These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23991920)

  • 1. Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?
    Cerchietti L; Melnick A
    Expert Rev Hematol; 2013 Aug; 6(4):343-5. PubMed ID: 23991920
    [No Abstract]   [Full Text] [Related]  

  • 2. AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.
    Jiao J; Lv Z; Zhang P; Wang Y; Yuan M; Yu X; Otieno Odhiambo W; Zheng M; Zhang H; Ma Y; Ji Y
    Neoplasia; 2020 Mar; 22(3):142-153. PubMed ID: 32062068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
    Cerchietti LC; Hatzi K; Caldas-Lopes E; Yang SN; Figueroa ME; Morin RD; Hirst M; Mendez L; Shaknovich R; Cole PA; Bhalla K; Gascoyne RD; Marra M; Chiosis G; Melnick A
    J Clin Invest; 2010 Dec; 120(12):4569-82. PubMed ID: 21041953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.
    Cerchietti LC; Yang SN; Shaknovich R; Hatzi K; Polo JM; Chadburn A; Dowdy SF; Melnick A
    Blood; 2009 Apr; 113(15):3397-405. PubMed ID: 18927431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic importance of BCL6 rearrangements in diffuse large B-cell lymphoma with respect to Bcl6 protein levels and primary lymphoma site.
    Tzankov A; Schneider A; Hoeller S; Dirnhofer S
    Hum Pathol; 2009 Jul; 40(7):1055-6; author reply 1056. PubMed ID: 19524106
    [No Abstract]   [Full Text] [Related]  

  • 6. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma.
    Saito M; Novak U; Piovan E; Basso K; Sumazin P; Schneider C; Crespo M; Shen Q; Bhagat G; Califano A; Chadburn A; Pasqualucci L; Dalla-Favera R
    Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11294-9. PubMed ID: 19549844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential transcription factor targeting for diffuse large B-cell lymphomas.
    Cerchietti LC; Polo JM; Da Silva GF; Farinha P; Shaknovich R; Gascoyne RD; Dowdy SF; Melnick A
    Cancer Res; 2008 May; 68(9):3361-9. PubMed ID: 18451163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.
    Borovecki A; Korać P; Nola M; Ivanković D; Jaksić B; Dominis M
    Croat Med J; 2008 Oct; 49(5):625-35. PubMed ID: 18925696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus microRNAs repress BCL6 expression in diffuse large B-cell lymphoma.
    Martín-Pérez D; Vargiu P; Montes-Moreno S; León EA; Rodríguez-Pinilla SM; Lisio LD; Martínez N; Rodríguez R; Mollejo M; Castellvi J; Pisano DG; Sánchez-Beato M; Piris MA
    Leukemia; 2012 Jan; 26(1):180-3. PubMed ID: 21788950
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of BCL6 in lymphomas and routes to therapy.
    Wagner SD; Ahearne M; Ko Ferrigno P
    Br J Haematol; 2011 Jan; 152(1):3-12. PubMed ID: 21083654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab.
    Kobayashi T; Tsutsumi Y; Sakamoto N; Nagoshi H; Yamamoto-Sugitani M; Shimura Y; Mizutani S; Matsumoto Y; Nishida K; Horiike S; Asano N; Nakamura S; Kuroda J; Taniwaki M
    Jpn J Clin Oncol; 2012 Nov; 42(11):1035-42. PubMed ID: 22984125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.
    Shustik J; Han G; Farinha P; Johnson NA; Ben Neriah S; Connors JM; Sehn LH; Horsman DE; Gascoyne RD; Steidl C
    Haematologica; 2010 Jan; 95(1):96-101. PubMed ID: 19797725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
    Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical profile and fluorescence in situ hybridization analysis of diffuse large B-cell lymphoma in northern China.
    Li T; Medeiros LJ; Lin P; Yin H; Littlejohn M; Im W; Lennon PA; Hu P; Jorgensen JL; Liang M; Guo H; Yin CC
    Arch Pathol Lab Med; 2010 May; 134(5):759-65. PubMed ID: 20441508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
    Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
    Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin D1-positive diffuse large B-cell lymphoma with IGH-CCND1 translocation and BCL6 rearrangement: a report of two cases.
    Al-Kawaaz M; Mathew S; Liu Y; Gomez ML; Chaviano F; Knowles DM; Orazi A; Tam W
    Am J Clin Pathol; 2015 Feb; 143(2):288-99. PubMed ID: 25596256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?
    Thieblemont C; Brière J
    Blood; 2013 Mar; 121(12):2165-6. PubMed ID: 23520325
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunoglobulin (Ig)/BCL6 versus non-Ig/BCL6 gene fusion in diffuse large B-cell lymphoma corresponds to a high- versus low-level expression of BCL6 mRNA.
    Ueda C; Uchiyama T; Ohno H
    Blood; 2002 Apr; 99(7):2624-5. PubMed ID: 11926184
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.
    Parekh S; Privé G; Melnick A
    Leuk Lymphoma; 2008 May; 49(5):874-82. PubMed ID: 18452090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
    Pasqualucci L; Migliazza A; Basso K; Houldsworth J; Chaganti RS; Dalla-Favera R
    Blood; 2003 Apr; 101(8):2914-23. PubMed ID: 12515714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.